Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L21 pseudogene 12 (RPL21P12) is a processed pseudogene of the functional ribosomal protein L21 (RPL21) gene[2][4]. Pseudogenes like RPL21P12 originate primarily from duplication or retrotransposition events involving their parent protein-coding genes—here, the parent gene is RPL21, which itself encodes a structural protein of the large 60S ribosomal subunit involved in protein synthesis[3][5]. As a pseudogene, RPL21P12 does not encode a functional protein product and is not a therapeutic target, receptor, enzyme, transporter, or similar entity[2][4]. The RPL21 gene has numerous pseudogenes throughout the genome, a typical feature for highly expressed "housekeeping" genes like ribosomal proteins[4]. There are no established roles for RPL21P12 in disease, no interacting drugs, and it does not serve as a biomarker or therapeutic target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L21 pseudogene 12 (RPL21P12).